GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (XCNQ:COOL) » Definitions » Buyback Yield %

Core One Labs (XCNQ:COOL) Buyback Yield % : -19.59 (As of May. 11, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Core One Labs Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Core One Labs's current buyback yield was -19.59%.


Core One Labs Buyback Yield % Historical Data

The historical data trend for Core One Labs's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs Buyback Yield % Chart

Core One Labs Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.60 -2.10 -62.74 -4.71 -23.88

Core One Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23 Dec23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -4.92 -28.08 - -

Competitive Comparison of Core One Labs's Buyback Yield %

For the Biotechnology subindustry, Core One Labs's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Core One Labs's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Core One Labs's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Core One Labs's Buyback Yield % falls into.



Core One Labs Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Core One Labs's Buyback Yield for the fiscal year that ended in Dec. 2021 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 3.585) / 15.0129
=-23.88%

Core One Labs's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 13.551352
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2023) data.


Core One Labs Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Core One Labs's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Core One Labs (XCNQ:COOL) Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5
Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.
Executives
Joel Shacker Director, Senior Officer